CCM
RARE icon

Cadian Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Cadian Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-627,203
Closed -$26M – 36
2022
Q3 		$26M Sell
627,203
-151,355
-19% -$7.78M 1.52% 19
2022
Q2 		$46.4M Buy
+778,558
New +$47.9M 3.14% 12

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Cadian Capital Management's RARE Position: Q4 2022 in Review

Cadian Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2022, closing a stake of 627,203 shares — an estimated $26M sold.

Cadian Capital Management first reported a position in RARE in Q2 2022 and held it in 2 quarters. The position peaked at $46.4M in Q2 2022. 228 funds tracked by Wall St. Rank hold RARE as of Q4 2022.

  • Cadian Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2022 after selling out during the quarter.
  • Cadian Capital Management sold 627,203 Ultragenyx Pharmaceutical shares in Q4 2022, an estimated $26M.
  • Cadian Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2022 and held it in 2 quarters.
  • Cadian Capital Management's Ultragenyx Pharmaceutical position peaked at $46.4M in Q2 2022.
  • 228 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2022.

Based on Cadian Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.